Contrast-enhanced ultrasonography in the development of sentinel lymph node of malignant melanoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025754

Enrollment

Unknown

Registered

2019-09-07

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma

Interventions

Gold Standard:Pathological staining analysis

Index test:Visualization&#32

of&#32

and&#32

lymph&#32

by&#32

ultrasound&#32

agents&#32

around&#32

melanoma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with confirmed skin melanoma, including preoperative and postoperative evaluation; (2) Patients who can achieve sentinel lymph node development after local injection of ultrasound contrast agent.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of surgery in the corresponding lymphatic drainage area of melanoma; (2) Patients who cannot achieve sentinel lymph node development after local injection of ultrasound contrast agent; (3) Patients with immune and metabolic diseases, and other tumors; (4) Any reason cannot be matched with the inspector.

Design outcomes

Primary

Measure	Time frame
Enhanced mode;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
Enhanced duration;	—

Countries

China

Contacts

Public ContactQiu Li

West China Hospital, Sichuan University

wsqiuli@126.com+86 18980602044

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026